Life Sciences Strategy and Transactions Consulting

EY-Parthenon Life Sciences Strategy and Transactions Consulting teams help develop and deliver transformative growth, transaction, digital and value-creation strategies. We help pharmaceuticals, MedTech, biopharma and other companies in the life sciences ecosystem build greater financial and operational resilience and technical agility, supporting their future growth and bringing new treatments to patients within an ever-changing landscape.


How Bristol Myers Squibb transformed cash management to fund its future

Discover how EY-Parthenon helped BMS unlock hundreds of millions in free cash flow and earn industry recognition for Treasury transformation. See how a cash-focused culture powers growth and innovation


What the EY-Parthenon Life Sciences Strategy and Transactions Consulting team can do for you

As the life sciences industry transforms in the face of regulatory and geopolitical uncertainty and new ways of developing treatments, EY-Parthenon teams can help you answer some of your most critical questions:

Transformative strategy

  • How should I refine my business strategy to find new avenues for growth while bringing innovative treatments to patients amid an ever-changing life sciences landscape?
  • How can I reimagine my operating model and go-to-market strategy?
  • How can I hone my organization’s strategy to strengthen its operational resilience?
  • How can I leverage cutting-edge technology and therapeutic platforms to discover the next life-saving treatment?

Transformative transactions

  • How can I leverage the ecosystem to scale and reach more patients effectively?
  • What type of transaction, joint venture or alliance will propel our organization’s growth and pair with consumer needs?
  • What is the right strategy to buy, build or partner to help reverse the innovation deficit?

EY-Parthenon Life Sciences Strategy and Transactions Consulting professionals can advise clients on developing transformative growth strategies by providing broad market, competitor and customer insights. But a strategy alone is not enough: We also help organizations execute strategy through real operational change. We help them transform the vision into reality by leveraging strategic, financial and operational perspectives based on deep sector experience and organizational knowledge to help enable execution to address society’s most pressing health problems.

Our focus includes:


EY-Parthenon Life Sciences Strategy and Transactions Consulting team

Our latest thinking

How IPO candidates can navigate uncertain and selective markets

The EY Global IPO Trends Q1 2026 explore how selectivity, geopolitics and investor expectations are shaping IPO access worldwide. Learn more.

How next-generation CRM will reshape the life sciences commercial model

CRM must evolve from analogue maps to real-time GPS for pharma. Unlock deeper insights—transform your customer engagement now. Read more.

EY Firepower report: life sciences dealmaking – trends in 2026

Learn how life sciences organizations can accelerate dealmaking strategies to succeed.



    Contact us
    Find out how EY-Parthenon Life Sciences Strategy and Transactions Consulting teams can support your transformative strategy and transactions.